Skip to content

D&A at other companies

Pfizer logo
PfizerPFE
$1.61B-0.3%
Amgen logo
AmgenAMGN
$1.12B-19.5%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$95.4M+3.0%
Biogen logo
BiogenBIIB
$204.4M+11.6%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$10.4M+14.3%
PBH
Prestige Consumer HealthcarePBH
$8.35M+15.2%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's D&A?
Organon (OGN) reported D&A of $39M in Q1 2026.
How has Organon's D&A changed year-over-year?
Organon's D&A increased by 14.7% year-over-year, from $34M to $39M.
What is the long-term trend for Organon's D&A?
Over 4 years (2021 to 2025), Organon's D&A has grown at a 14.1% compound annual growth rate (CAGR), from $92M to $156M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.